OBJECTIVE: To explore whether fluorescence emission spectroscopy of blood components can differentiate normal from early and advanced stages of breast cancer using stepwise discriminant analysis. MATERIALS AND METHODS: Fluorescence emission spectra were measured for blood components of three different groups: 35 normal controls, 28 with early-stage, and 18 with advanced-stage breast cancer. The data from the spectra were subjected to Fisher's linear discriminant analysis. Classification accuracy, specificity, and sensitivity of the technique were calculated for breast cancer diagnosis. RESULTS: Fluorescence emission spectra of blood components accurately distinguished normal from early-stage and advanced-stage breast cancer in 91.4% of original cases and 90.1% for cross-validated cases. The sensitivity and specificity were 80.4% and 100%, respectively, in distinguishing subjects with breast cancer from normal controls. CONCLUSION: Our statistical evaluation indicates that porphyrin in blood can be used as a reliable tumor marker. Fluorescence emission spectroscopy of blood components and statistical evaluations should be further investigated for a variety of tumors.
OBJECTIVE: To explore whether fluorescence emission spectroscopy of blood components can differentiate normal from early and advanced stages of breast cancer using stepwise discriminant analysis. MATERIALS AND METHODS: Fluorescence emission spectra were measured for blood components of three different groups: 35 normal controls, 28 with early-stage, and 18 with advanced-stage breast cancer. The data from the spectra were subjected to Fisher's linear discriminant analysis. Classification accuracy, specificity, and sensitivity of the technique were calculated for breast cancer diagnosis. RESULTS: Fluorescence emission spectra of blood components accurately distinguished normal from early-stage and advanced-stage breast cancer in 91.4% of original cases and 90.1% for cross-validated cases. The sensitivity and specificity were 80.4% and 100%, respectively, in distinguishing subjects with breast cancer from normal controls. CONCLUSION: Our statistical evaluation indicates that porphyrin in blood can be used as a reliable tumor marker. Fluorescence emission spectroscopy of blood components and statistical evaluations should be further investigated for a variety of tumors.
Authors: Flávia R O Silva; Camila T Nabeshima; Maria H Bellini; Nestor Schor; Nilson D Vieira; Lilia C Courrol Journal: J Fluoresc Date: 2012-09-09 Impact factor: 2.217
Authors: Daniel Riani Gotardelo; Lilia Coronato Courrol; Maria Helena Bellini; Flávia Rodrigues de Oliveira Silva; Carlos Roberto Jorge Soares Journal: BMC Cancer Date: 2018-11-12 Impact factor: 4.430
Authors: Rasmus Bro; Hans Jørgen Nielsen; Francesco Savorani; Karin Kjeldahl; Ib Jarle Christensen; Nils Brünner; Anders Juul Lawaetz Journal: Metabolomics Date: 2012-07-18 Impact factor: 4.290
Authors: Philipp Brunnbauer; Annekatrin Leder; Can Kamali; Kaan Kamali; Eriselda Keshi; Katrin Splith; Simon Wabitsch; Philipp Haber; Georgi Atanasov; Linda Feldbrügge; Igor M Sauer; Johann Pratschke; Moritz Schmelzle; Felix Krenzien Journal: Sci Rep Date: 2018-10-31 Impact factor: 4.379